For the quarter ended September 2023, PTC Therapeutics (PTCT - Free Report) reported revenue of $196.58 million, down 9.5% over the same period last year. EPS came in at -$1.76, compared to -$1.53 in the year-ago quarter.
The reported revenue represents a surprise of -13.18% over the Zacks Consensus Estimate of $226.43 million. With the consensus EPS estimate being -$0.85, the EPS surprise was -107.06%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how PTC Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Net product revenue: $144.04 million versus the six-analyst average estimate of $153.29 million. The reported number represents a year-over-year change of +7.3%.
- Revenues- Royalty revenue: $50.17 million versus the six-analyst average estimate of $49.62 million.
- Revenues- Net product revenue- Emflaza: $67 million versus $58.92 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +21.8% change.
- Revenues- Net product revenue- Translarna: $69 million versus the five-analyst average estimate of $68.63 million. The reported number represents a year-over-year change of -10.4%.
View all Key Company Metrics for PTC Therapeutics here>>>Shares of PTC Therapeutics have remained unchanged over the past month versus the Zacks S&P 500 composite's -3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
For the quarter ended September 2023, PTC Therapeutics (PTCT - Free Report) reported revenue of $196.58 million, down 9.5% over the same period last year. EPS came in at -$1.76, compared to -$1.53 in the year-ago quarter.
The reported revenue represents a surprise of -13.18% over the Zacks Consensus Estimate of $226.43 million. With the consensus EPS estimate being -$0.85, the EPS surprise was -107.06%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how PTC Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Net product revenue: $144.04 million versus the six-analyst average estimate of $153.29 million. The reported number represents a year-over-year change of +7.3%.
- Revenues- Royalty revenue: $50.17 million versus the six-analyst average estimate of $49.62 million.
- Revenues- Net product revenue- Emflaza: $67 million versus $58.92 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +21.8% change.
- Revenues- Net product revenue- Translarna: $69 million versus the five-analyst average estimate of $68.63 million. The reported number represents a year-over-year change of -10.4%.
View all Key Company Metrics for PTC Therapeutics here>>>Shares of PTC Therapeutics have remained unchanged over the past month versus the Zacks S&P 500 composite's -3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Get the latest research report on PTCT - FREE